Supernus Pharmaceuticals, Inc. (Nasdaq: SUPPORT), a biopharmaceutical company focused on the development and commercialization of products for the treatment of diseases of the central nervous system (CNS), announced today that the United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. and its subsidiary, Torrent Pharma Inc., infringed US patent numbers 8,992,989; 9,549,940; and 9,622,983 by submitting to the US Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) requesting permission to market a generic version of Trokendi XR® before the expiration of the Supernus patents .
"We are very pleased with the District Court's ruling that Torrent infringed our Trokendi XR® patents and the reaffirmation of the validity of those patents," said Jack A. Khattar, president and CEO of Supernus Pharmaceuticals. "We take very seriously the protection of intellectual property (IP) for our innovative products and the aggressive enforcement of such intellectual property rights, even if the product is at a later stage in its life cycle."
In addition to the three patents that were the subject of the District Court's decision, Trokendi XR® is protected by seven other patents. The Orange Book lists a total of ten patents covering Trokendi XR.